Naslov
Insulin detemir - a novel basal insulin

Autori
Pavlić-Renar, Ivana ; Prašek, Manja ; Djojić, Mirela

Izvornik
Diabetologia Croatica (0351-0042) 32 (2003), 4; 163-167

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
detemir; insulin analogs; basal insulin

Sažetak
Insulin detemir is a soluble long-acting insulin analogue developed to provide low, constant, and reproducible plasma insulin supply for up to 24 hours. Acylation of a 14-carbon chain fatty acid (myristic acid) to the lysine residue at position B29 of the insulin molecule results in delayed absorption due to both increased self-association at the injection site and a high degree of reversible albumin binding. The combination of protracted absorption from the injection site and delayed action due to albumin binding provides a prolonged and predictable action profile with low within-subject day-to-day variation. From the published phase III trials, effect of insulin detemir as basal insulin is same or better in comparison with NPH in terms of achieving glycaemic control estimated by HbA1c. There is clearly lower within subject variability of insulin effect with insulin detemir than with NPH or glargine thus making the effect more predictable. In most studies, number of hypoglycemic events, especially nocturnal, is smaller with insulin detemir than with NPH. In comparison to NPH insulin, insulin detemir was associated with less weight gain. A designed basal insulin should be peakless with low variability, ie. with more predictable action thus enabling better glycaemic control with less hypoglycemia, safe and easy to handle. Insulin detemir seems to fulfill these demands.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA